Comparative Pharmacology
Head-to-head clinical analysis: THEROXIDIL versus TRANSDERM NITRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEROXIDIL versus TRANSDERM NITRO.
THEROXIDIL vs TRANSDERM-NITRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theroxidil is a vasodilator that acts by opening potassium channels in vascular smooth muscle, leading to hyperpolarization and relaxation. It also inhibits platelet aggregation and reduces peripheral vascular resistance.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
5 mg orally once daily, increased to 10 mg after 4 weeks as tolerated.
Initial dose 0.2-0.4 mg/hour transdermally once daily. Titrate to 0.4-0.8 mg/hour. Maximum 0.8 mg/hour.
None Documented
None Documented
Terminal elimination half-life 24-30 hours; steady-state reached after 4-5 days; clinically significant for once-daily dosing
Terminal elimination half-life is approximately 1-4 minutes after IV administration due to rapid metabolism. After transdermal application, the apparent half-life is 3-4 hours due to continued absorption from the skin depot, resulting in a prolonged clinical effect.
Approximately 60% renal (15% unchanged, 45% as glucuronide metabolites), 40% fecal/biliary as metabolites
Renal (primarily) and biliary; ~60-80% of the dose is excreted renally as metabolites, with <1% unchanged. Fecal excretion accounts for ~10-20%.
Category C
Category C
Vasodilator
Vasodilator